Business
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial Magnetic Stimulation (TMS) machines nationwide.Program will unite common treatment protocols and clinical training with neurocare expertise in neuromodulation technology and NRx Pharmaceuticals neuroplastic drug development program.Pilot program with a state first-responder agency has demonstrated high rates of success in combining TMS, neuroplastic drug treatment, hyperbaric oxygen, and psychotherapy to achieve remission from PTSD and Depression in First Responders.neurocare and NRx look forward to offering an integrated treatment program to patients and payers within driving distance of any American home by year-end 2026. WILMINGTON, Del. and MUNICH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company and neurocare Group AG today (“The Partners”) announced a partnership to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. Pilot programs have shown that combining Transcranial Magnetic Stimulation (TMS) with ketamine and other neuroplastic drugs, along with hyperbaric oxygen therapy and supportive psychotherapy has resulted in a high rate of remission among First Responders with PTSD and Depression. Recent scientific publications have demonstrated that integration of TMS with neuroplastic drugs has achieved unprecedented response of 87% and remission of 72% in patients with treatment-resistant depression. While these results are early and will require further study, they are highly encouraging. The Partners are additionally exploring joint regulatory paths including clinical trials to address the treatment of Bipolar Depression, Autism, and Traumatic Brain Injury with TMS and neuroplastic drugs, such as NRX-101. Although there have been a number of clinic chains founded to combine some of these therapies in the past, a fully-integrated nationwide program that combines these neuroplastic modalities with common training protocols, advanced use of Telepsychiatry and Information Technology, and payer outreach has not been achieved. This approach was successful in creating reliable and effective approaches to t...